Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
Source: View publication →
The PROTECT AF trial demonstrated that percutaneous closure of the left atrial appendage with the Watchman device was non-inferior to warfarin for stroke prevention in non-valvular atrial fibrillation, though it was associated with higher upfront procedural safety events.
Key Findings
Study Design
Study Limitations
Clinical Significance
PROTECT AF was a landmark study that established percutaneous left atrial appendage (LAA) closure as a viable, non-pharmacologic alternative to warfarin for stroke prophylaxis in patients with non-valvular atrial fibrillation. By proving non-inferiority to the standard of care, it introduced a major paradigm shift for patients who are suitable for short-term anticoagulation but desire to avoid the bleeding risks and monitoring burdens of lifelong systemic anticoagulation. The trial also highlighted the critical need for operator training to mitigate early procedural hazards.
Historical Context
Prior to PROTECT AF, the undisputed standard for stroke prevention in non-valvular atrial fibrillation was systemic anticoagulation with warfarin. However, warfarin's narrow therapeutic window, numerous drug-food interactions, and bleeding risks resulted in widespread underutilization. Based on transesophageal echocardiography and autopsy data showing that over 90% of atrial thrombi in non-valvular AF originate in the LAA, researchers hypothesized that mechanically excluding the appendage could prevent stroke. PROTECT AF was the pivotal randomized trial validating this concept, eventually leading to FDA approval of the Watchman device after further safety refinements were demonstrated in the subsequent PREVAIL trial.
Guided Discussion
High-yield insights from every perspective
Why is the left atrial appendage specifically targeted for percutaneous closure in patients with non-valvular atrial fibrillation, and how does the pathophysiology differ from valvular atrial fibrillation?
Key Response
In non-valvular atrial fibrillation, over 90 percent of thrombi originate in the left atrial appendage due to blood stasis from the loss of coordinated atrial contraction. In valvular atrial fibrillation, such as with mitral stenosis, stasis occurs throughout the globally dilated left atrium, meaning left atrial appendage closure alone would be insufficient for stroke prevention.
Given the initial PROTECT AF findings of higher upfront procedural complications with the Watchman device compared to warfarin, how should you counsel a patient with non-valvular atrial fibrillation and a high HAS-BLED score about this intervention?
Key Response
Residents must weigh procedural risks, such as pericardial effusion and procedural stroke, against the long-term bleeding risks of anticoagulation. Counseling involves explaining that while the device offers freedom from long-term anticoagulation, it carries an acute procedural risk, requiring shared decision-making based on the patient's individual bleeding risk and ability to tolerate a short-term post-procedural antithrombotic regimen.
The PROTECT AF protocol required patients to remain on warfarin for 45 days post-implantation. How does this requirement complicate the use of the Watchman device in patients who have absolute contraindications to systemic anticoagulation?
Key Response
Fellows should understand the clinical paradox of left atrial appendage closure: the procedure is often most desired for patients who cannot tolerate anticoagulation, yet the trial protocol required 45 days of warfarin to prevent device thrombosis until endothelialization occurred. This necessitates knowledge of alternative off-label antiplatelet regimens or newer trial data for patients with absolute contraindications.
How do we interpret the non-inferiority of left atrial appendage closure established in PROTECT AF in the context of the modern era where direct oral anticoagulants are the standard of care rather than warfarin?
Key Response
Attendings must integrate legacy trial data with current practice. PROTECT AF compared the Watchman to warfarin. Today, direct oral anticoagulants are generally safer and more effective than warfarin. Therefore, the modern risk-benefit calculus for left atrial appendage closure must implicitly account for the improved safety profile of direct oral anticoagulants, raising the threshold to recommend an invasive procedure.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
PROTECT AF used a non-inferiority margin of 2.0 for the rate ratio of the primary efficacy endpoint. In the context of a composite endpoint including both ischemic and hemorrhagic stroke, how does this margin affect the interpretation of the device's true efficacy in preventing ischemic events?
Key Response
A non-inferiority trial with a wide margin on a composite endpoint can mask worse performance in one component, like ischemic stroke, if offset by better performance in another, like hemorrhagic stroke, which inherently decreases off warfarin. Methodologists must evaluate if the non-inferiority margin is clinically acceptable for each individual component.
As a reviewer, what concerns would you raise regarding the unblinded nature of the PROTECT AF trial and the potential for detection bias or variations in the control arm's Time in Therapeutic Range?
Key Response
Unblinded trials with procedural interventions are highly susceptible to performance and detection bias. A critical reviewer would scrutinize whether the warfarin arm achieved adequate Time in Therapeutic Range, as poor warfarin control could falsely inflate the relative efficacy and safety of the device arm.
Based on the PROTECT AF findings and subsequent registry data, what Class of Recommendation should be assigned to percutaneous left atrial appendage closure, and how should guidelines position it relative to direct oral anticoagulant therapy?
Key Response
Current AHA/ACC/HRS guidelines give percutaneous left atrial appendage closure a Class 2b recommendation for patients with non-valvular atrial fibrillation at increased risk of stroke who have contraindications to long-term anticoagulation. The committee must balance the long-term non-inferiority shown in PROTECT AF against the lack of head-to-head randomized data against direct oral anticoagulants, positioning it as a second-line option.
Clinical Landscape
Noteworthy Related Trials
PREVAIL Trial
Tested
Watchman LAA closure device
Population
Patients with non-valvular atrial fibrillation
Comparator
Warfarin therapy
Endpoint
Composite of stroke, systemic embolism, and cardiovascular/unexplained death
PRAGUE-17 Trial
Tested
Percutaneous LAA closure
Population
Patients with non-valvular atrial fibrillation at high risk for stroke and bleeding
Comparator
Direct oral anticoagulants (DOACs)
Endpoint
Composite of stroke, TIA, systemic embolism, CV death, major bleeding, or procedure complications
LAAOS III Trial
Tested
Surgical occlusion of the left atrial appendage
Population
Patients with atrial fibrillation undergoing cardiac surgery for another reason
Comparator
No surgical LAA occlusion
Endpoint
Ischemic stroke or systemic embolism
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis